Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. is an American clinical-stage biopharmaceutical company developing RNA interference (RNAi) therapeutics. The company utilizes its proprietary Targeted RNAi Molecule (TRiM) platform to silence disease-causing genes across liver, pulmonary, and cardiometabolic disorders. Its clinical pipeline features RNAi therapeutic candidates targeting hypertriglyceridemia, hepatitis B, amyloidosis, and cardiovascular conditions. Primary revenue drivers are biopharmaceutical collaboration milestone payments, upfront licensing fees, and research funding from pharmaceutical partners. Arrowhead Pharmaceuticals holds a market-leading position in RNAi drug delivery technology. The company is headquartered in Pasadena, California, and its shares trade on the Nasdaq Global Select Market.
12 of the funds FundTelligence covers report a position in Arrowhead Pharmaceuticals.
- Legal name
- Arrowhead Pharmaceuticals Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 12
- Exposure themes
- Genetic Medicine, Precision Medicine & Genomics, RNA Therapeutics
Funds holding Arrowhead Pharmaceuticals
- Nordea BetaPlus Enhanced Global Sustainable Small Cap — Nordea Funds · 0.85 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.8 % (full portfolio disclosed, October 2026)
- SEB Läkemedelsfond — SEB · 0.72 % (full portfolio disclosed, June 2026)
- Fondsfinans Global Helse — Fondsfinans · 0.57 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.53 % (full portfolio disclosed, October 2026)
- Schroder ISF Global Convertible Bond — Schroders · 0.15 % (full portfolio disclosed, June 2026)
- KLP AksjeGlobal Small Cap Flerfaktor — KLP · 0.12 % (full portfolio disclosed, June 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.09 % (partially disclosed portfolio, June 2026)
Showing the 8 largest of 12 funds holding it.